-
公开(公告)号:US20110281888A1
公开(公告)日:2011-11-17
申请号:US13108024
申请日:2011-05-16
申请人: Mark J. Mulvihill , Amo G. Steinig , Andrew Philip Crew , Meizhong Jin , Andrew Kleinberg , An-Hu Li , Jing Wang
发明人: Mark J. Mulvihill , Amo G. Steinig , Andrew Philip Crew , Meizhong Jin , Andrew Kleinberg , An-Hu Li , Jing Wang
IPC分类号: A61K31/497 , A61P35/00 , A61K31/437 , C07D471/04 , C07D401/14
CPC分类号: C07D471/04
摘要: Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.
摘要翻译: 式I化合物,如下文所示和定义:其药学上可接受的盐,合成,中间体,制剂及其治疗方法,包括治疗癌症,例如至少部分地通过至少一种RON, MET或ALK。 本发明并不限于本发明。
-
公开(公告)号:US07659274B2
公开(公告)日:2010-02-09
申请号:US11657156
申请日:2007-01-24
IPC分类号: A61K31/4985
CPC分类号: C07D487/04
摘要: Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
摘要翻译: 由式(I)表示的化合物或其药学上可接受的盐是mTOR的抑制剂,可用于治疗癌症。
-
23.Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders 失效
标题翻译: 吡咯并[2,3-D]咪唑用于治疗过度增殖性疾病公开(公告)号:US07498354B2
公开(公告)日:2009-03-03
申请号:US11397031
申请日:2006-03-30
IPC分类号: A61K31/4162 , C07D235/00
CPC分类号: C07D487/04
摘要: or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of tumors and cancers.
摘要翻译: 或其药学上可接受的盐或N-氧化物可用于治疗肿瘤和癌症。
-
-